Journals / Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi / 2005 / Cilt: 6 - Sayı: 2

Comparsion of the effects in intranasal and transdermal estradiol plus dydrogestorone on lipids, lipoprotein (A) and apoliproteins in postmenopausal women

Didrogesteron ile intranazal ve transdermal östradiol kombinasyonunun lipid, lipoprotein (A) ve apolipoproteinlere etkilerinin karşılaştırılması

Pages
3–8
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, in transdermal estradiol group, no significant changes were seeninall variables.Nosignificant difference swith regard to variables were noted between the groups at the endof the study.Conclusions: The effects of intranasal and transdermal estradiol plus dydrogestorone as a continouos hormone replacement therapy on the serum total cholesterol, triglyceride, HDL, LDL, VLDL, lipoprotein(a) andApoA-I levels are similar in postmenopausal women.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective:To compare the effects of continuous hormon replacement therapy in the form of intranasal and transdermal 17β- estradiol combined with dydrogesterone on serum lipids, lipoprotein(a) and apolipoproteins among postmenopausal women.
📊
Key Findings & Data:Materials and methods: In this prospective study, 50 healthy postmenopausal women aged 43-54 years were randomly assigned to receive either 300 µg/day intranasal 17 β- estradiol (n=25) or 50 µg/day transdermal 17 β- estradiol (n=25) for 12 weeks.All women also received 10 mg/day oral dydrogesterone continuously.At the end of the study, changes in serumtotal cholesterol, triglyceride, HDL, LDL,VLDL, lipoprotein(a),Apo A-I and Apo B levels within and percent changes between the groups were compared.
💡
Conclusion & Impact:Also, in transdermal estradiol group, no significant changes were seeninall variables.Nosignificant difference swith regard to variables were noted between the groups at the endof the study.Conclusions: The effects of intranasal and transdermal estradiol plus dydrogestorone as a continouos hormone replacement therapy on the serum total cholesterol, triglyceride, HDL, LDL, VLDL, lipoprotein(a) andApoA-I levels are similar in postmenopausal women.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective:To compare the effects of continuous hormon replacement therapy in the form of intranasal and transdermal 17β- estradiol combined with dydrogesterone on serum lipids, lipoprotein(a) and apolipoproteins among postmenopausal women. Materials and methods: In this prospective study, 50 healthy postmenopausal women aged 43-54 years were randomly assigned to receive either 300 µg/day intranasal 17 β- estradiol (n=25) or 50 µg/day transdermal 17 β- estradiol (n=25) for 12 weeks.All women also received 10 mg/day oral dydrogesterone continuously.At the end of the study, changes in serumtotal cholesterol, triglyceride, HDL, LDL,VLDL, lipoprotein(a),Apo A-I and Apo B levels within and percent changes between the groups were compared. Mann-Whitney U and Wilcoxon tests were usedas indicated. P-values below 0.05 were considered significant.Results: Thirty-four women completed this study (intranasal group, n=16; transdermal group, n=18). In intranasal estradiol group, only apolipoprotein B levels were decreased significantly after 12 weeks of treatment (2.0±0.4 to 0.9±0.1, p=0.028) whereas no changes in the levels of total cholesterol, triglyceride, HDL, LDL, VLDL, lipoprotein(a) and ApoA-I were observed. Also, in transdermal estradiol group, no significant changes were seeninall variables.Nosignificant difference swith regard to variables were noted between the groups at the endof the study.Conclusions: The effects of intranasal and transdermal estradiol plus dydrogestorone as a continouos hormone replacement therapy on the serum total cholesterol, triglyceride, HDL, LDL, VLDL, lipoprotein(a) andApoA-I levels are similar in postmenopausal women.

Özet

Amaç: Bu araştırmanın amacı, postmenopozal kadınlarda, intranazal ve transdermal 17β-östradiol ile didrogesteronun kombine kesintisiz hormon replasman tedavisinin, serumlipid, lipoprotein(a) ve apolipoprotein düzeyleri üzerindeki etkilerini karşılaştırmaktır. Gereç ve Yöntem: Bu prospektif araştırmaya yaşları 43-54 arasında değişen, sağlıklı 50 postmenopozal kadın dahil edildi. Olgular, 12 hafta süre ile 300 µ g/gün intranazal 17 β- östradiol (n=25) veya 50 µg/gün transdermal kesintisiz verildi. Araştırmanın başında ve sonunda, total kolesterol, trigliserid, HDL, LDL, VLDL, lipoprotein(a), Apo A-I ve Apo B düzeyleri, grup içi ve gruplar arasında farkın yüzdeleri karşılaştırıldı. İstatistiksel analiz için Mann-Whitney U ve Wilcoxon testi kullanıldı. P

🔖

Cite This Article

DEMİRCAN, S., ONUR, E., KAFKAS, S., ERKAN, P., YÜKSEL, H., ODABAŞI, A. R. (2022). Comparsion of the effects in intranasal and transdermal estradiol plus dydrogestorone on lipids, lipoprotein (A) and apoliproteins in postmenopausal women. Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, Cilt: 6 - Sayı: 2, 3–8. https://ajindex.com/articles/429052

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 2002;16:329-55
  2. Stampfer MJ, Colditz GA, Willet WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med1991;325:756-62
  3. Longcope C, Gorbach S, Goldin B et al. The metabolism of estrodiol: oral compared to intravenous administration. J Steroid Biochem1985;23:1065-70
  4. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898- 915
  5. Hulley S, Furberg C, Barret-Connor E et al; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERSII). JAMA 2002;288:58-66 6) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33
  6. Stanczyk FZ, Shoupe D, Nunez V et al.Arandomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6
  7. Frenkel Y, Kopernik G, Lazer S et al.Acceptability and skin reactions to transdermal estrogen replacement therapyin relationto climate.Maturitas 1994;20:31-6
  8. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud1993;38:5-11
  9. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmocokinetics of intranasal 17- beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmocokinet 1999;24:265-71
  10. Mattsson LA, Christiansen C, Colau JC et al. Clinical equivalance of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-52
  11. Voetberg GA, Netelenbos JC, Kenemans P et al. Estrogen replacement therapy continuously combined withfour different dosages of dydrogesterone: effect on calciumand lipidmetabolism. J Clin Endocrinol Metab 1994;79:1465-9
  12. Foster RH, Balfour JA. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. D